Literature DB >> 33801562

Insights from Cardiopulmonary Exercise Testing in Pediatric Patients with Hypertrophic Cardiomyopathy.

Giovanna Gallo1, Vittoria Mastromarino2, Giuseppe Limongelli3, Giulio Calcagni4, Antonello Maruotti5,6,7, Luca Ragni2, Fabio Valente3, Maria Beatrice Musumeci1, Rachele Adorisio4, Marta Rubino3, Camillo Autore1, Damiano Magrì1.   

Abstract

The usefulness of cardiopulmonary exercise test (CPET) in adult hypertrophic cardiomyopathy (HCM) patients is well-known, whereas its role in pediatric HCM patients has not yet been explored. The present study investigates possible insights from a CPET assessment in a cohort of pediatric HCM outpatients in terms of functional and prognostic assessment. Sixty consecutive pediatric HCM outpatients aged <18 years old were enrolled, each of them undergoing a full clinical assessment including a CPET; a group of 60 healthy subjects served as controls. A unique composite end-point of heart failure (HF) related and sudden cardiac death (SCD) or SCD-equivalent events was also explored. During a median follow-up of 53 months (25th-75th: 13-84 months), a total of 13 HF- and 7 SCD-related first events were collected. Compared to controls, HCM patients showed an impaired functional capacity with most of them showing peak oxygen uptake (pVO2) values of <80% of the predicted, clearly discrepant with functional New York Heart Association class assessment. The composite end-point occurred more frequently in patients with the worst CPETs' profiles. At the univariate analysis, pVO2% was the variable with the strongest association with adverse events at follow-up (C-index = 0.72, p = 0.025) and a cut-off value equal to 60% was the most accurate in identifying those patients at the highest risk. In a pediatric HCM subset, the CPET assessment allows a true functional capacity estimation and it might be helpful in identifying early those patients at high risk of events.

Entities:  

Keywords:  cardiopulmonary exercise test; clinical assessment; hypertrophic cardiomyopathy; pediatric

Mesh:

Year:  2021        PMID: 33801562      PMCID: PMC7999553          DOI: 10.3390/biom11030376

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  40 in total

1.  New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome.

Authors:  Charlene Bredy; Margherita Ministeri; Alexander Kempny; Rafael Alonso-Gonzalez; Lorna Swan; Anselm Uebing; Gerhard-Paul Diller; Michael A Gatzoulis; Konstantinos Dimopoulos
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2018-01-01

Review 2.  Cardiopulmonary Exercise Testing in Pediatrics.

Authors:  Tim Takken; Bart C Bongers; Marco van Brussel; Eero A Haapala; Erik H J Hulzebos
Journal:  Ann Am Thorac Soc       Date:  2017-07

3.  Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study.

Authors:  Damiano Magrì; Piergiuseppe Agostoni; Filippo Maria Cauti; Beatrice Musumeci; Gabriele Egidy Assenza; Carlo Nicola De Cecco; Giuseppe Muscogiuri; Antonello Maruotti; Agnese Ricotta; Erika Pagannone; Laura Marino; Daria Santini; Giulia Proietti; Andrea Serdoz; Francesco Paneni; Massimo Volpe; Camillo Autore
Journal:  Intern Emerg Med       Date:  2012-10-07       Impact factor: 3.397

Review 4.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

5.  Isovolumic relaxation period in hypertrophic cardiomyopathy: assessment by radionuclide angiography.

Authors:  S Betocchi; R O Bonow; S L Bacharach; D R Rosing; B J Maron; M V Green
Journal:  J Am Coll Cardiol       Date:  1986-01       Impact factor: 24.094

6.  Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart.

Authors:  Sara Saberi; Sharlene M Day
Journal:  Circulation       Date:  2018-01-30       Impact factor: 29.690

Review 7.  Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis.

Authors:  Gabrielle Norrish; Nicoletta Cantarutti; Eleni Pissaridou; Deborah A Ridout; Giuseppe Limongelli; Perry M Elliott; Juan Pablo Kaski
Journal:  Eur J Prev Cardiol       Date:  2017-05-09       Impact factor: 7.804

8.  Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment.

Authors:  Gherardo Finocchiaro; Francois Haddad; Joshua W Knowles; Colleen Caleshu; Aleksandra Pavlovic; Julian Homburger; Yael Shmargad; Gianfranco Sinagra; Emma Magavern; Myo Wong; Marco Perez; Ingela Schnittger; Jonathan Myers; Victor Froelicher; Euan A Ashley
Journal:  JACC Heart Fail       Date:  2015-04-08       Impact factor: 12.035

9.  Exercise haemodynamic variables rather than ventilatory efficiency indexes contribute to risk assessment in chronic heart failure patients treated with carvedilol.

Authors:  Ugo Corrà; Alessandro Mezzani; Andrea Giordano; Enzo Bosimini; Pantaleo Giannuzzi
Journal:  Eur Heart J       Date:  2009-12       Impact factor: 29.983

10.  Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing.

Authors:  Damiano Magrì; Vittoria Mastromarino; Giovanna Gallo; Elisabetta Zachara; Federica Re; Piergiuseppe Agostoni; Dario Giordano; Speranza Rubattu; Maurizio Forte; Maria Cotugno; Maria Rosaria Torrisi; Simona Petrucci; Aldo Germani; Camilla Savio; Antonello Maruotti; Massimo Volpe; Camillo Autore; Maria Piane; Beatrice Musumeci
Journal:  J Clin Med       Date:  2020-05-28       Impact factor: 4.241

View more
  1 in total

1.  Family screening of hypertrophic cardiomyopathy in children: a case report.

Authors:  Inga Voges; Heiner Latus
Journal:  Eur Heart J Case Rep       Date:  2022-09-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.